Ragweed Clinical Trial

TITLE:
A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study Evaluating the Efficacy and Long-term Safety of Ragweed (Ambrosia Artemisiifolia) Sublingual Tablet (SCH 09641) in Adults With a History of Ragweed-induced Rhinoconjunctivitis With or Without Asthma

PURPOSE:
To evaluate the efficacy of the ragweed sublingual tablet versus placebo in treating ragweed-induced rhinoconjunctivitis based on a combined daily symptom score of rhinoconjunctivitis and rhinoconjunctivitis daily medication averaged over the entire ragweed season.

PHASE:
2/3

INSTITUTIONAL REVIEW BOARD:
Stirling Institutional Review Board

STATUS:
Closed to enrollment

ELIGIBILITY:
People aged 18 to 50 years with a clinical history of significant ragweed-induced allergic rhinoconjunctivitis with or without asthma.

DURATION:
11 visits over 60 weeks

PRINICPAL INVESTIGATOR:
Kerry S. LeBenger, MD

SUB-INVESTIGATOR:
Gary Pien, MD

CONTACT:
Genevieve Barragan, CRC
908-277-8642